Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Autor: Jason S. McLellan, C. Garrett Rappazzo, James C. Geoghegan, Longping V. Tse, John M. Dye, James E. Voss, Dennis R. Burton, Jonathan P. Belk, Laura M. Walker, Linlin Yang, Yixuan J. Hou, Chengzi I. Kaku, Andrew S. Herbert, Mrunal Sakharkar, Ralph S. Baric, Laura M. Deveau, Trevor Scobey, David Nemazee, Thomas J. Yockachonis, Michael E. Brown, Daniel Wrapp, Bronwyn M. Gunn, Linghang Peng, Cecilia M. O’Brien, Michael B. Battles, Deli Huang, Lisa E. Gralinski
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Science
ISSN: 1095-9203
0036-8075
DOI: 10.1126/science.abf4830
Popis: Targeting sarbecoviruses As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survivor of the 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries to introduce diversity into these antibodies, and then screened for binding to SARS-CoV-2. One of the affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, and two SARS-related viruses from bats. In addition, this antibody bound to the receptor-binding domains from a panel of sarbecoviruses, suggesting broader activity, and provided protection against SARS-CoV and SARS-CoV-2 in mouse models. Science , this issue p. 823
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje